[1] L.M.Z.d. Aguiar, L. Antonangelo, F.S. Vargas, M.C.N. Zerbini, M.M. Sales, D.E. Uip, P.H.N. Saldiva, Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization, Clinics (Sao Paulo, Brazil) 63(5) (2008) 637-644.
[2] K. Oshikawa, K. Yanagisawa, S. Ohno, S.-I. Tominaga, Y. Sugiyama, Expression of ST2 in Helper T Lymphocytes of Malignant Pleural Effusions, American journal of respiratory and critical care medicine 165 (2002) 1005-9.
[3] R.A. Seder, R. Ahmed, Similarities and differences in CD4+ and CD8+ effector and memory T cell generation, Nature Immunology 4(9) (2003) 835-842.
[4] H.L. Lee, J.W. Jang, S.W. Lee, S.H. Yoo, J.H. Kwon, S.W. Nam, S.H. Bae, J.Y. Choi, N.I. Han, S.K. Yoon, Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization, Scientific Reports 9(1) (2019) 3260.
[5] E. Choy, S. Rose-John, Interleukin-6 as a Multifunctional Regulator: Inflammation, Immune Response, and Fibrosis, Journal of Scleroderma and Related Disorders 2(2_suppl) (2017) S1-S5.
[6] C. Gabay, Interleukin-6 and chronic inflammation, Arthritis Research & Therapy 8(2) (2006) S3.
[7] S. Diehl, M. Rincón, The two faces of IL-6 on Th1/Th2 differentiation, Molecular Immunology 39(9) (2002) 531-536.
[8] D.R. Lucey, M. Clerici, G.M. Shearer, Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases, Clin Microbiol Rev 9(4) (1996) 532-562.
[9] J.L. Flynn, J. Chan, P.L. Lin, Macrophages and control of granulomatous inflammation in tuberculosis, Mucosal Immunology 4(3) (2011) 271-278.
[10] Y.-M. Chen, W.-K. Yang, J. Whang-Peng, C.-M. Tsai, R.-P. Perng, An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer, Lung Cancer 31(1) (2001) 25-30.
[11] E.A. Lieser, W.K. Croghan Ga Fau - Nevala, M.J. Nevala Wk Fau - Bradshaw, S.N. Bradshaw Mj Fau - Markovic, A.S. Markovic Sn Fau - Mansfield, A.S. Mansfield, Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions, (1872-8332 (Electronic)).
[12] M.A. Ghayumi, Z. Mojtahedi, M.J. Fattahi, Th1 and Th2 cytokine profiles in malignant pleural effusion, Iranian Journal of Immunology 8(4) (2011) 195-200.
[13] A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Journal of Clinical Epidemiology 62(10) (2009) e1-e34.
[14] S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample, BMC Medical Research Methodology 5(1) (2005) 13.
[15] C. Alemán, J. Alegre, J. Monasterio, R.M. Segura, L. Armadans, A. Anglés, E. Varela, E. Ruiz, T. Fernández De Sevilla, Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions, Clinical Science 105(5) (2003) 601-607.
[16] A. Ali, T. Mohmoud, Differential diagnostic efficiency of T cells subsets versus interferon-gamma, tumor necrosis factor-alpha, and adenosine deaminase in distinguishing tuberculous from malignant pleural effusions, Chest 148(4) (2015).
[17] V. Ambade, M.M. Arora, S.P. Rai, S.K. Nikumb, D.R. Basannar, Markers for differentiation of tubercular pleural effusion from non-tubercular effusion, Medical Journal Armed Forces India 67(4) (2011) 338-342.
[18] H.M. Atef, A.A. Okab, G.F. Al Mehy, M.M. El Beheisy, The role of tumor necrosis factor alpha in differentiation between malignant and non malignant pleural effusion, Egyptian Journal of Chest Diseases and Tuberculosis 65(3) (2016) 605-612.
[19] F. Budak, E.K. Uzaslan, S. Cangür, G. Göral, H.B. Oral, Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines, Lung 186(5) (2008) 337-43.
[20] A. Ciledag, A. Kaya, S. Erol, E. Sen, G. Celik, S. Cesur, Y. Fidan, S. Kinikli, The comparison of pleural fluid TNF-alpha and IL-10 levels with ADA in tuberculous pleural effusion, Curr Med Chem 17(19) (2010) 2096-100.
[21] Z.D. Daniil, E. Zintzaras, T. Kiropoulos, A.I. Papaioannou, A. Koutsokera, A. Kastanis, K.I. Gourgoulianis, Discrimination of exudative pleural effusions based on multiple biological parameters, Eur Respir J 30(5) (2007) 957-64.
[22] J. Gao, L. Song, D. Li, L. Peng, H. Ding, Clinical value of haptoglobin and soluble CD163 testing for the differential diagnosis of tuberculous and malignant pleural effusions, Medicine 98(42) (2019) e17416.
[23] E.A. Hamed, A.M. El-Noweihi, A.Z. Mohamed, A. Mahmoud, Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions, Respirology 9(1) (2004) 81-6.
[24] L.Y. Huang, H.Z. Shi, Q.L. Liang, Y.B. Wu, X.J. Qin, Y.Q. Chen, Expression of soluble triggering receptor expression on myeloid cells-1 in pleural effusion, Chinese Medical Journal 121(17) (2008) 1656-1661.
[25] D. Iglesias Sáenz, J. Alegre, C. Alemán, E. Ruíz, T. Soriano, L.I. Armadans, R.M. Segura, A. Anglés, J. Monasterio, T.F. de Sevilla, Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions, European Respiratory Journal 25(1) (2005) 104-109.
[26] T.S. Kiropoulos, K. Kostikas, S. Oikonomidi, I. Tsilioni, D. Nikoulis, A. Germenis, K.I. Gourgoulianis, Acute phase markers for the differentiation of infectious and malignant pleural effusions, Respir Med 101(5) (2007) 910-8.
[27] M.H. Lee, C.H. Nahm, J.W. Choi, Thrombin-antithrombin III complex, proinflammatory cytokines, and fibrinolytic indices for assessing the severity of inflammation in pleural effusions, Ann Clin Lab Sci 40(4) (2010) 342-7.
[28] M. Li, H. Wang, X. Wang, J. Huang, J. Wang, X. Xi, Diagnostic accuracy of tumor necrosis factor-alpha, interferon-gamma, interleukin-10 and adenosine deaminase 2 in differential diagnosis between tuberculous pleural effusion and malignant pleural effusion, J Cardiothorac Surg 9 (2014) 118.
[29] H. Liu, S. Wang, Z. Zhang, J. Jie, L. Song, S. Hua, Diagnostic Value of Soluble Form of Mer Tyrosine Kinase (sMerTK) in Tuberculous Pleural Effusion and Malignant Pleural Effusion, BioMed Research International 2020 (2020).
[30] H. Momi, W. Matsuyama, K. Inoue, M. Kawabata, K. Arimura, H. Fukunaga, M. Osame, Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions, Respir Med 96(10) (2002) 817-22.
[31] Q. Qian, W.K. Sun, P. Zhan, Y. Zhang, Y. Song, L.K. Yu, Role of monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma, Int J Biol Markers 27(2) (2012) e118-24.
[32] M. Wang, Z. Zhang, X. Wang, Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions, Clinics (Sao Paulo) 69(12) (2014) 799-803.
[33] Y. Yamada, A. Nakamura, M. Hosoda, T. Kato, T. Asano, K. Tonegawa, M. Itoh, Cytokines in pleural liquid for diagnosis of tuberculous pleurisy, Respir Med 95(7) (2001) 577-81.
[34] Y.M. Chen, W.K. Yang, J. Whang-Peng, C.M. Tsai, R.P. Perng, An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer, Lung Cancer 31(1) (2001) 25-30.
[35] H.Y. Cui, Q. Zhang, B. Su, W. Li, S.J. Tang, Differential levels of cytokines and soluble fas ligand between tuberculous and malignant effusions, Journal of International Medical Research 38(6) (2010) 2063-2069.
[36] L. Ibrahim, M. Salah, A.A.E. Rahman, A. Zeidan, M. Ragb, Crucial role of CD4+CD 25+ FOXP3+ T regulatory cell, interferon-γ and interleukin-16 in malignant and tuberculous pleural effusions, Immunological Investigations 42(2) (2013) 122-136.
[37] R. Krenke, A. Safianowska, M. Paplinska, J. Nasilowski, B. Dmowska-Sobstyl, E. Bogacka-Zatorska, A. Jaworski, R. Chazan, Pleural fluid adenosine deaminase and interferon- gammaas diagnostic tools in tuberculous pleurisy, Journal of Physiology and Pharmacology 59(SUPPL. 6) (2008) 349-360.
[38] K.S. Lee, H.R. Kim, S. Kwak, K.H. Choi, J.H. Cho, Y.J. Lee, M.K. Lee, J.H. Lee, S.D. Park, D.S. Park, Association between elevated pleural interleukin-33 levels and tuberculous pleurisy, Annals of Laboratory Medicine 33(1) (2013) 45-51.
[39] M.A.M. Marie, J. John, L.G. Krishnappa, S. Gopalkrishnan, S.R. Bindurani, Role of interleukin-6, gamma interferon and adenosine deaminase markers in management of pleural effusion patients, West Indian Medical Journal 62(9) (2013) 803-807.
[40] M. Okamoto, Y. Hasegawa, T. Hara, N. Hashimoto, K. Imaizumi, K. Shimokata, T. Kawabe, T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions, Chest 128(6) (2005) 4030-4035.
[41] M. Okamoto, T. Kawabe, Y. Iwasaki, T. Hara, N. Hashimoto, K. Imaizumi, Y. Hasegawa, K. Shimokata, Evaluation of interferon-gamma, interferon-gamma-inducing cytokines, and interferon-gamma-inducible chemokines in tuberculous pleural effusions, J Lab Clin Med 145(2) (2005) 88-93.
[42] L. Valdés, E.S. José, J.M.A. Dobaño, A. Golpe, J.M. Valle, P. Penela, F.J.G. Barcala, Diagnostic value of interleukin-12 p40 in tuberculous pleural effusions, European Respiratory Journal 33(4) (2009) 816-820.
[43] L. Valdés, E.S. José, L. Ferreiro, A. Golpe, F. Gude, J.M. Álvarez-Dobaño, M.F. Pereyra, M.E. Toubes, F.J. González-Barcala, Interleukin 27 could be useful in the diagnosis of tuberculous pleural effusions, Respiratory Care 59(3) (2014) 399-405.
[44] Y.B. Wu, Z.J. Ye, S.M. Qin, C. Wu, Y.Q. Chen, H.Z. Shi, Combined detections of interleukin 27, interferon-γ, and adenosine deaminase in pleural effusion for diagnosis of tuberculous pleurisy, Chin Med J (Engl) 126(17) (2013) 3215-21.
[45] K. Xue, S. Xiong, W. Xiong, Clinical value of vascular endothelial growth factor combined with interferon-gamma in diagnosing malignant pleural effusion and tuberculous pleural effusion, J Huazhong Univ Sci Technolog Med Sci 27(5) (2007) 495-7.
[46] S. Yurt, C. Küçükergin, B.A. Yigitbas, Ş. Seçkin, H.C. Tigin, A.F. Koşar, Diagnostic utility of serum and pleural levels of adenosine deaminase 1-2, and interferon-γ in the diagnosis of pleural tuberculosis, Multidisciplinary Respiratory Medicine 9(1) (2014).
[47] M. Zhang, D. Xiong, H. Li, Z. Wang, R. Li, Diagnostic value of T-spot TB combined with INF-γ and IL-27 in tuberculous pleurisy, Experimental and Therapeutic Medicine 15(2) (2018) 1871-1874.
[48] C.C. Shu, J.Y. Wang, C.L. Hsu, L.T. Keng, K. Tsui, J.F. Lin, H.C. Lai, C.J. Yu, L.N. Lee, K.T. Luh, Diagnostic role of inflammatory and anti-inflammatory cytokines and effector molecules of cytotoxic T lymphocytes in tuberculous pleural effusion, Respirology 20(1) (2015) 147-54.
[49] J. Zhang, Y. Chen, G. He, X. Jiang, P. Chen, J. Ouyang, Differential diagnosis of tuberculous and malignant pleural effusions: comparison of the Th1/Th2 cytokine panel, tumor marker panel and chemistry panel, Scand J Clin Lab Invest 80(4) (2020) 265-270.
[50] K.Y. Chen, P.H. Feng, C.C. Chang, T.T. Chen, H.C. Chuang, C.N. Lee, C.L. Su, L.Y. Lin, K.Y. Lee, Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion, Int J Gen Med 9 (2016) 183-9.
[51] R.N. Dalil, M. Marjani, N.K. Dezfuli, P. Tabarsi, A. Moniri, M. Varahram, I.M. Adcock, E. Mortaz, Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion, Sci Rep 11(1) (2021) 660.
[52] R. El Sayed, A. Okab, M. El-Mahdy, I. Kasb, Y. Ismail, Role of interleukin-6 (IL-6) in diagnosis of malignant pleural mesothelioma, Egyptian Journal of Chest Diseases and Tuberculosis 64(2) (2015) 419-424.
[53] L. Ferreiro, Ó. Lado-Baleato, J. Suárez-Antelo, M. Toubes, M. San José, A. Lama, N. Rodríguez-Núñez, J. Álvarez-Dobaño, F. González-Barcala, J. Ricoy, F. Gude, L. Valdés, Diagnosis of infectious pleural effusion using predictive models based on pleural fluid biomarkers, Annals of Thoracic Medicine 14(4) (2019) 254-263.
[54] L.R. Teixeira, M.B. Dias, R.K.B. Sales, L. Antonangelo, V.A. Alvarenga, J. Puka, E. Marchi, M.M.P. Acencio, Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions, Lung 194(6) (2016) 1021-1027.
[55] N. Xirouchaki, N. Tzanakis, D. Bouros, D. Kyriakou, N. Karkavitsas, M. Alexandrakis, N.M. Siafakas, Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions, Chest 121(3) (2002) 815-20.
[56] Y.C. Liu, S. Shin-Jung Lee, Y.S. Chen, H.Z. Tu, B.C. Chen, T.S. Huang, Differential diagnosis of tuberculous and malignant pleurisy using pleural fluid adenosine deaminase and interferon gamma in Taiwan, Journal of Microbiology, Immunology and Infection 44(2) (2011) 88-94.
[57] I.V. Lyadova, A.V. Panteleev, Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers, Mediators Inflamm 2015 (2015) 854507-854507.
[58] Y.V.N. Cavalcanti, M.C.A. Brelaz, J.K.d.A.L. Neves, J.C. Ferraz, V.R.A. Pereira, Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis, Pulm Med 2012 (2012) 745483-745483.
[59] P.L. Lin, H.L. Plessner, N.N. Voitenok, J.L. Flynn, Tumor Necrosis Factor and Tuberculosis, Journal of Investigative Dermatology Symposium Proceedings 12(1) (2007) 22-25.
[60] V. Nagabhushanam, L.-M. Solache A Fau - Ting, C.J. Ting Lm Fau - Escaron, J.Y. Escaron Cj Fau - Zhang, J.D. Zhang Jy Fau - Ernst, J.D. Ernst, Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma, (0022-1767 (Print)).
[61] S. Diehl, A. Anguita J Fau - Hoffmeyer, T. Hoffmeyer A Fau - Zapton, J.N. Zapton T Fau - Ihle, E. Ihle Jn Fau - Fikrig, M. Fikrig E Fau - Rincón, M. Rincón, Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1, (1074-7613 (Print)).
[62] B. Carow, D. Ye Xq Fau - Gavier-Widén, S. Gavier-Widén D Fau - Bhuju, W. Bhuju S Fau - Oehlmann, M. Oehlmann W Fau - Singh, M. Singh M Fau - Sköld, L. Sköld M Fau - Ignatowicz, A. Ignatowicz L Fau - Yoshimura, H. Yoshimura A Fau - Wigzell, M.E. Wigzell H Fau - Rottenberg, M.E. Rottenberg, Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner, (1083-351X (Electronic)).
[63] P.S. Redford, P.J. Murray, A. O'Garra, The role of IL-10 in immune regulation during M. tuberculosis infection, Mucosal Immunology 4(3) (2011) 261-270.
[64] A.H.K. Ali, T.M. Mahmoud, H. Ahmed, Differential diagnostic efficiency of T cells subsets versus interferon-gamma, tumor necrosis factor-alpha and adenosine deaminase in distinguishing tuberculous from malignant pleural effusions, Egyptian Journal of Chest Diseases and Tuberculosis 64(3) (2015) 645-651.
[65] A. Pooran, M. Davids, A. Nel, A. Shoko, J. Blackburn, K. Dheda, IL-4 subverts mycobacterial containment in <em>Mycobacterium tuberculosis</em>-infected human macrophages, European Respiratory Journal 54(2) (2019) 1802242.
[66] D.G. DeNardo, J.B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, N. Kolhatkar, L.M. Coussens, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell 16(2) (2009) 91-102.
[67] W. Lin, H.-l. Zhang, Z.-y. Niu, Z. Wang, Y. Kong, X.-s. Yang, F. Yuan, The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden, BMC Women's Health 20(1) (2020) 126.
[68] M.R. Shurin, L. Lu, P. Kalinski, A.M. Stewart-Akers, M.T. Lotze, Th1/Th2 balance in cancer, transplantation and pregnancy, Springer Seminars in Immunopathology 21(3) (1999) 339-359.
[69] A. Sparano, D.M.R. Lathers, N. Achille, G.J. Petruzzelli, M.R.I. Young, Modulation of Th1 and Th2 Cytokine Profiles and Their Association with Advanced Head and Neck Squamous Cell Carcinoma, Otolaryngology–Head and Neck Surgery 131(5) (2004) 573-576.
[70] D. Atanackovic, A. Block, A. de Weerth, C. Faltz, D.K. Hossfeld, S. Hegewisch-Becker, Characterization of Effusion-Infiltrating T Cells, Clinical Cancer Research 10(8) (2004) 2600.
[71] H. Maeda, A. Shiraishi, TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice, (0022-1767 (Print)).
[72] F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille, M. Bréban, B. Pallot-Prades, S. Pouplin, A. Sacchi, R.M. Chichemanian, S. Bretagne, D. Emilie, M. Lemann, O. Lortholary, X. Mariette, G. Research Axed on Tolerance of Biotherapies, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry, Arthritis Rheum 60(7) (2009) 1884-1894.
[73] J. Qiao, Z. Liu, C. Dong, Y. Luan, A. Zhang, C. Moore, K. Fu, J. Peng, Y. Wang, Z. Ren, C. Han, T. Xu, Y.-X. Fu, Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis, Cancer Cell 35(6) (2019) 901-915.e4.
[74] A. Suzuki, P. Leland, B.H. Joshi, R.K. Puri, Targeting of IL-4 and IL-13 receptors for cancer therapy, Cytokine 75(1) (2015) 79-88.